Values of fibrinogen in relation to segmental involvement of the venous system in patients with recurrent deep vein thrombosis
Abstract
Introduction: The occurrence of recurrent venous thrombosis,
despite adequate therapy, is still a topic of research in the scientific
world. The site of thrombosis and the involvement of anatomical
segments represent a significant factor in its occurrence.
Aim: To correlate fibrinogen values with anatomical location
and extent of verified thrombus in patients with recurrent deep
vein thrombosis.
Materials and methods: In the period January 2007-January
2020, 223 patients with recurrent deep vein thrombosis were
analyzed. At admission fibrinogen values were taken.
Results: There was no significant difference in fibrinogen values
in relation to gender (p = 0.842). The difference in mean
fibronogen values between proximal (n = 171) and distal (n =
27 = veins) were not statistically significant (p = 0.326). There
was no difference between the average values of fibrinogen in
relation to the number of segments (1 to 3) (p = 0.298). The
largest number of patients (n = 132) had 2 segments affected,
and fibrinogen values was 4.7 g/L (3.6-7.1 g/L). Male gender
had slightly higher fibrinogen values than females, but without
significance (p = 0.091). The age of the subjects did not
correlate with fibrinogen values ( p = 0.569). Fibrinogen values
according to vein anatomical localization were statistically
non-significant (p = 0.201).
Conclusion: Fibrinogen values were not proved to be an indicator
of anatomical localization and segmental involvement in
patients with recurrent DVT.
Keywords: fibrinogen, venous thrombosis, prognosis.
Full Text:
PDFReferences
Tiscia GL, Margaglione M. Human Fibrinogen: Molecular
and Genetic Aspects of Congenital Disorders. Int J Mol Sci.
;19(6):1597.
Tennent GA, Brennan SO, Stangou AJ, O’Grady J, Hawkins
PN, Pepys MB. Human plasma fibrinogen is synthesized in
the liver. Blood. 2007;109:1971–1974
Pieters M, Wolberg AS. Fibrinogen and fibrin: An illustrated
review. Research and Practice in Thrombosis and Haemostasis.
Apr;3(2):161-172.
van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen
are associated with the risk of deep venous thrombosis
mainly in the elderly. J Thromb Haemost. 2003;1:2677–
Aleman MM, Walton BL, Byrnes JR, Wolberg AS. Fibrinogen
and red blood cells in venous thrombosis. Thromb Res.
;133 (1):S38-S40.
Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska
A, Skubiszak A, Ciepluch K, et al. Altered fibrin clot
structure/function in patients with idiopathic venous thromboembolism
and in their relatives. Blood. 2009;114:4272–
Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and Fibrin in
Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol.
;37(3):e13-e21.
Wolberg AS, Campbell RA. Thrombin generation, fibrin
clot formation and hemostasis. Transfus Apher Sci.
;38(1):15-23. doi:10.1016/j.transci.2007.12.005
Obradovic S, Begic E, Jankovic S, Romanovic R, Djenic N,
Dzudovic B, et al. Association of PC and AT levels in the
early phase of STEMI treated with pPCI with LV systolic
function and 6-month MACE [published online ahead of
print, 2020 May 21]. Acta Clin Belg. 2020;1-7.
Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance
for the practical management of warfarin therapy in the
treatment of venous thromboembolism. J Thromb Thrombolysis.
;41(1):187-205.
Heit JA. Epidemiology of venous thromboembolism. Nat
Rev Cardiol. 2015;12(8):464-474.
Heit JA, Spencer FA, White RH. The epidemiology of venous
thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-
Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis:
pathogenesis, diagnosis, and medical management. Cardiovasc
Diagn Ther. 2017;7(3):S276-S284.
Oklu R, Albadawi H, Watkins MT, et al. Detection of extracellular
genomic DNA scaffold in human thrombus: implications
for the use of deoxyribonuclease enzymes in thrombolysis.
J Vasc Interv Radiol. 2012;23:712-8
Asim M, Al-Thani H, El-Menyar A. Recurrent Deep Vein
Thrombosis After the First Venous Thromboembolism
Event: A Single-Institution Experience. Med Sci Monit.
;23:2391-2399.
Konstantinides SV, Meyer G, Becattini C, ESC Scientific
Document Group. 2019 ESC Guidelines for the diagnosis
and management of acute pulmonary embolism developed
in collaboration with the European Respiratory Society
(ERS). Eur Heart J. 2020;41(4):543–603.
Mlaco A, Mlaco N, Bejtovic D, Dzubur A, Spuzic M. Venous
Thromboembolism During Ten-year Follow up on
Clinical Center University of Sarajevo. Mater Sociomed.
;31(2):84-87.
Mlaco A, Mlaco N, Bejtovic D, Spuzic M, Dzubur A, Begic
E. Provoked venous thromboembolism during ten-year
follow up at the Clinical Centre University of Sarajevo [published
online ahead of print, 2020 Feb 1]. Med Glas (Zenica).
;17(1):10.17392/1038-20.
Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs
R, et al. Diagnosis and management of acute deep
vein thrombosis: a joint consensus document from the European
Society of Cardiology working groups of aorta and
peripheral vascular diseases and pulmonary circulation and
right ventricular function. Eur Heart J. 2018;39(47):4208-
Labropoulos N, Jen J, Jen H, Gasparis AP, Tassiopoulos AK.
Recurrent deep vein thrombosis: long-term incidence and
natural history. Ann Surg. 2010;251(4):749-753.
Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism
after deep vein thrombosis: incidence and risk
factors. Arch Intern Med. 2000;160(6):769-774.
Farzamnia H, Rabiei K, Sadeghi M, Roghani F. The predictive
factors of recurrent deep vein thrombosis. ARYA Atheroscler.
;7(3):123-128.
Wuillemin WA, Korte W, Waser G, Lammle B. Usefulness
of the D-dimer/fibrinogen Ratio to Predict Deep Venous
Thrombosis. J Thromb Haemost. 2005 Feb;3(2):385-7.
Klovaite J, Nordestgaard BG, Tybjærg-Hansen A, Benn M.
Elevated fibrinogen levels are associated with risk of pulmonary
embolism, but not with deep venous thrombosis.
American Journal of Respiratory and Critical Care Medicine.
Feb;187(3):286-293.
Wolberg AS. Fibrinogen and factor XIII: newly recognized
roles in venous thrombus formation and composition. Current
Opinion in Hematology. 2018 Sep;25(5):358-364.
Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice
D. Systematic review of prognostic models for recurrent
venous thromboembolism (VTE) post-treatment of first unprovoked
VTE. BMJ Open. 2016;6(5):e011190.
Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod
G, Kahn SR; REVERSE II Study Investigators. Validating
the HERDOO2 rule to guide treatment duration for
women with unprovoked venous thrombosis: multinational
prospective cohort management study. BMJ. 2017 Mar
;356:j1065.
Timp JF, Lijfering WM, Rosendaal FR, le Cessie S, Cannegieter
SC. Risk prediction of recurrent venous thrombosis;
where are we now and what can we add? Journal of Thrombosis
and Haemostasis : JTH. 2019 Sep;17(9):1527-1534.
Refbacks
- There are currently no refbacks.